A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

Roche

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: Erlotinib

Study type: Observational

Funder types: Industry

Identifiers

NCT02595450

ML22190

Details and patient eligibility

About

This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.

Enrollment: 299 patients

Sex: All

Ages: 35 to 86 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• It is the physician's decision to prescribe erlotinib in participants and to document their treatment
• Participants must be candidates for receiving erlotinib for locally advanced or metastatic non-small cell lung cancer according to the product label

Exclusion criteria

• Participants will be excluded if safety concerns occurred
• If the participant was not compliant or if the participant would wish to stop erlotinib therapy

Trial design

299 participants in 1 patient group

Erlotinib

Description:

Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.

Treatment:

Drug: Erlotinib